Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approval sought for frontline Tevimbra (tislelizumab) in locally advanced or metastatic esophageal squamous cell carcinoma – BeiGene

Written by | 27 Sep 2023 | ENT

The FDA has accepted for review a biologics license application (BLA) seeking the approval of tislelizumab (Tevimbra) for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

The application is supported by findings from the phase III RATIONALE 306 (NCT03783442) in which the addition of tislelizumab to chemotherapy (n = 326) resulted in improved overall survival (OS) vs placebo plus chemotherapy (n = 323), at a median of 17.2 months (95% CI, 15.8-20.1) vs 10.6 months (95% CI, 9.3-12.1), respectively (stratified HR, 0.66; 95% CI, 0.54-0.80; P < .0001). The 12-month OS rates in the investigative and control arms were 65.0% (95% CI, 59.4%-70.0%) and 44.9% (95% CI, 39.2%-50.3%), respectively; the 18-month rates were 48.6% (95% CI, 42.9%-54.0%) and 34.5% (95% CI, 29.2%-39.8%), respectively.

Under the Prescription Drug User Fee Act, the regulatory agency has assigned a target action date in the second half of 2024.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.